Elusys Therapeutics, Inc.
25 Riverside Drive
P.O. Box 102
53 articles with Elusys Therapeutics, Inc.
Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government
Heat Biologics, Inc. announced to shareholders that its Elusys Therapeutics subsidiary has finalized a contract with the Canadian government to deliver ANTHIM®, a treatment for inhalation anthrax, for use against a potential anthrax attack.
Heat Biologics, Inc. today announced it has completed the acquisition of Elusys Therapeutics, Inc.
Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, Its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services
Elusys Therapeutics, Inc. (Elusys) announced today that it has finalized a contract with the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) for the continued supply of ANTHIM (obiltoxaximab), an anthrax antitoxin, for use against a potential anthrax attack.
Heat Biologics, Inc. today announced it has executed a definitive merger agreement to acquire Elusys Therapeutics, a commercial-stage biodefense company and the manufacturer of ANTHIM® (obiltoxaximab) Injection, pursuant to which Elusys will merge into a wholly owned subsidiary of Heat.
Obiltoxaximab Receives Marketing Authorization From European Commission For The Treatment Of Inhalation Anthrax
Elusys Therapeutics, Inc. announced that the European Commission has approved obiltoxaximab, the company's monoclonal antibody anthrax antitoxin for the treatment of inhalation anthrax.
Elusys Therapeutics Receives Positive CHMP Opinion For Obiltoxaximab SFL For The Treatment Of Inhalation Anthrax
Elusys Therapeutics, Inc. (Elusys) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending marketing authorization under exceptional circumstances for Obiltoxaximab SFL (obiltoxaximab),
Elusys Receives Second Delivery Order From U.S. Government for ANTHIM®, its Treatment for Inhalation Anthrax
Elusys receives $19.7 million for delivery of ANTHIM under first Delivery Order
Elusys Therapeutics, Inc. Delivers First Shipment Of Anthim, Its Treatment For Inhalation Anthrax, To The U.S. Government Strategic National Stockpile
Elusys Therapeutics, Inc. Release: Company Receives $16.35 Million For Delivery Of ANTHIM To U.S. Government
Elusys Therapeutics, Inc. Announces Publication Of Data Establishing The Adult Human Dose For Its Inhalational Anthrax Antitoxin, ANTHIM (obiltoxaximab) Injection
Elusys Therapeutics, Inc. Announces Publication Of Results From Five Clinical Trials With Its Inhalational Anthrax Antitoxin, ANTHIM (obiltoxaximab) Injection
Elusys Therapeutics, Inc. Announces That Manuscripts For Its Anthrax Antitoxin, ANTHIM (Obiltoxaximab) Injection, Have Been Accepted For Publication
Elusys Therapeutics, Inc. Receives FDA Approval For ANTHIM (obiltoxaximab) Injection For The Treatment And Prophylaxis Of Inhalational Anthrax
Elusys Therapeutics, Inc. Receives First Delivery Order From U.S. Government For Anthim (obiltoxaximab) For Treatment Of Inhalational Anthrax
Elusys Therapeutics, Inc. Awarded Additional $16 Million Under Existing U.S. Government Contract To Complete Development Of Lyophilized Form Of Anthim (Obiltoxaximab) For Treatment Of Inhalational Anthrax
Elusys Therapeutics, Inc. Release: U.S. FDA Accepts Biologics License Application For Anthim (Obiltoxaximab)
Elusys Therapeutics, Inc. Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program
Elusys Therapeutics, Inc. Completes Commercial Manufacturing Process Validation For Anthrax Antitoxin ETI-204
Elusys Therapeutics, Inc. Completes Enrollment In Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, ETI-204, In Adult Volunteers
Elusys Therapeutics, Inc. Releases New Data on Anthrax Anti-Toxin Administered Via Intramuscular Injection From Three Recent Animal Studies